Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 17OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm Metastasis 1Epidermolysis Bullosa Dystrophica 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 328Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 280Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × OTHER × ON 01910 × Clear all
NCT03786237 2026-02-24

Rigosertib for RDEB-SCC

Salzburger Landeskliniken

Phase 1/2 Completed
2 enrolled

Carcinoma, Squamous Cell, Epidermolysis Bullosa Dystrophica

NCT04263090 2024-05-09

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
25 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡